Frequent and effective engagement with our internal and external stakeholders is critical for us to develop and operationalise our sustainability strategy and related disclosures. It also enables us to better understand how stakeholder expectations and needs might align with the long-term sustainability of our business.
To create a safe, sustainable and performance-driven working environment with a culture that drives innovation and delivers on the Group’s objectives and goals
Training and development pathways
Engagement surveys
Company events to facilitate connection and collaboration
Proactive and inclusive internal communication forums
Health, safety, wellbeing and environment (HSWE) programs
To ensure our innovation and pipeline development remains connected to patient needs and experience
Key opinion leader strategy
Product and disease area advisory boards
Direct connections with patient and patient advocacy groups (subject to local laws for engagement)
To mitigate risk and ensure our commercial-stage and development-stage assets meet customers' needs
Participation in scientific and medical congresses
Direct communication
Fair and balanced medical and scientific education about our products and innovation
To communicate the strategy and governance that supports our delivery and performance
Investor communications strategy and dedicated investor relations team
Direct engagement with shareholders and investors
Hybrid Annual General Meetings which enable direct feedback to Directors from the widest possible group of shareholders
Engagement program for governance and proxy advisors
Investor roadshows and webinars
To lift the profile of theranostics, and partner with governments to create systems that encourage and incentivise innovation and access to the latest technologies
Lead industry collaboration with policy makers, highlighting the unique and complex nature of personalised nuclear medicine and its high value to society
Contribute to policy initiatives that improve healthcare system readiness for theranostics, across governance, regulation and reimbursement, service provision, workforce and health information
To support sustainable business growth and deliver access to a range of diagnostics and therapies
Conduct diligence and risk assessments of our contract research, development and manufacturing organisations and other material supply chain vendors
Foster connections between material supply chain partners to facilitate collaboration to achieve objectives
Alignment on shared sustainable business growth and other institutional partnerships